Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin vs Simulect in High-Risk Renal Transplant
NCT00235300Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2000
- Primary completion
- Apr 2003
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of antithymocyte globulin in kidney transplant rejection, delayed graft function (DGF), sponsored by Sanofi. Started May 2000; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
kidney transplant rejectiondelayed graft function (DGF)
Beyond the preview
Go deeper on NCT00235300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00235300.